Takeda Pharmaceutical Co ADR(TAK) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -0.34 | Insider Own | - | Shs Outstand | 3.18B | Perf Week | -0.11% |
| Market Cap | 57.95B | Forward P/E | 29.14 | EPS next Y | 60% | Insider Trans | - | Shs Float | 3.18B | Perf Month | 3.76% |
| Enterprise Value | 85.51B | PEG | 1.13 | EPS next Q | 0.15 | Inst Own | 3.29% | Short Float | 0.09% | Perf Quarter | 15.84% |
| Income | -1.05B | P/S | 1.94 | EPS this Y | 1.46% | Inst Trans | 0.5% | Short Ratio | 0.95 | Perf Half Y | - |
| Sales | 29.91B | P/B | 1.24 | EPS next 5Y | 25.69% | ROA | -1.08% | Short Interest | 2.99M | Perf YTD | 16.81% |
| Book/sh | 14.71 | P/C | 20.43 | EPS past 3/5Y | - | ROE | -2.22% | 52W High | -3.63% ($18.90) | Perf Year | 19.25% |
| Cash/sh | 0.89 | P/FCF | 13.29 | Sales past 3/5Y | 0.19% -0.17% | ROIC | -1.42% | 52W Low | 40.18% ($12.99) | Perf 3Y | 19.72% |
| Dividend Est. | $0.64 (3.52%) | EV/EBITDA | 9.23 | EPS Y/Y TTM | -208.74% | Gross Margin | 54.53% | Volatility(W/M) | 1.4% 1.13% | Perf 5Y | 7.24% |
| Dividend TTM | 0.63 | EV/Sales | 2.86 | Sales Y/Y TTM | -0.14% | Oper. Margin | 15.28% | ATR (14) | 0.29 | Perf 10Y | -20.06% |
| Dividend Ex-Date | 2026/3/31 | Quick Ratio | 0.62 | EPS Q/Q | -18.22% | Profit Margin | -3.49% | RSI (14) | 56.42 | Recom | 1.94 |
| Dividend Gr. 3/5Y | 1.18% -5.75% | Current Ratio | 1.14 | Sales Q/Q | - | SMA20 | 0.69% ($18.09) | Beta | -0.05 | Target Price | $20.42 |
| Payout | - | Debt/Eq | 0.65 | Earnings | 2026/7/30 | SMA50 | 4.74% ($17.39) | Rel Volume | 0.46 | Prev Close | $18.32 |
| Employees | 47029 | LT Debt/Eq | 0.58 | EPS/Sales Surpr. | 33.21% 7.4% | SMA200 | 8.36% ($16.81) | Avg Volume(3M) | 3.16M | Price | $18.21 |
| IPO | 2008/3/6 | Option/Short | Yes/Yes | Trades | 6500 | Volume | 1,437,375 | Change | -0.6% |
Company
TAK is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
💊 Takeda Pharmaceutical is a global pharmaceutical company representing Japan, listed on the US NYSE in ADR form. It holds a broad therapeutic area portfolio that includes oncology, rare diseases, neuroscience, gastroenterology, plasma-derived therapies, and vaccines, and is characterized by a multinational sales network and a stable operating structure based at its Japanese headquarters.
Over the past 1 year, on the higher side
4% below its 1-year high.
TAK has weak earning power
15.28% of revenue is kept as operating profit.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +1.5% this year.
Tap to view numbers
The price looks about right
Trading at - times earnings.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 3 quarters.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Buy.
Tap to view numbers
Long-term returns are close to the market
Would have changed by +19.7% if bought 5 years ago.
Tap to view numbers
Dividends are paid consistently
Pays 3.52% annually in dividends.
Tap to view numbers
Ownership looks stable
Institutions hold 3.3%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
IDNA 0.04%
PPH 0.03%
ASD 0.02%
BINV 0.02%
AADR 0.02%It is the largest in the industry
Based on market cap of $58B.
TAK $58B PER -
TEVA $43B PER 62.0
HLN $41B PER 19.0
ZTS $30B PER 12.1
FAQ
What kind of company is TAK?
TAK belongs to the Healthcare sector and operates in the Drug Manufacturers - Specialty & Generic industry.
What is the market cap of TAK?
The market cap of TAK is approximately $57.9B, ranking 292 within its sector.
Does TAK pay dividends?
TAK has a dividend yield of approximately 3.52%, with an annual dividend of $0.64.
What is the 52-week high and low for TAK?
TAK has recorded a 52-week high of $18.90 and a low of $12.99.
